$CTIC Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in CTI BIOPHARMA CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in CTI BIOPHARMA CORP. Get notifications about new insider transactions in CTI BIOPHARMA CORP for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 05 2021 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | Director | Option Exercise | P | 0.00 | 17 | 0 | 17 | |
Apr 05 2021 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | Director | Option Exercise | P | 0.00 | 239 | 0 | 239 | |
Apr 05 2021 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | Director | Option Exercise | P | 0.00 | 344 | 0 | 344 | |
Apr 05 2021 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | Director | Buy | P | 2.50 | 5,171 | 12,928 | 488,879 | 483.7 K to 488.9 K (+1.07 %) |
Apr 05 2021 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | Director | Buy | P | 2.50 | 950,016 | 2,375,040 | 3,059,296 | 2.1 M to 3.1 M (+45.04 %) |
Apr 05 2021 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | Director | Buy | P | 2.50 | 1,044,813 | 2,612,033 | 4,085,933 | 3 M to 4.1 M (+34.36 %) |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | Tuckson Reed Vaughn | Director | Option Exercise | A | 3.30 | 80,000 | 264,000 | 80,000 | |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | Metzger Michael A | Director | Option Exercise | A | 3.30 | 80,000 | 264,000 | 80,000 | |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | PERRY MATTHEW D | Director | Option Exercise | A | 3.30 | 80,000 | 264,000 | 80,000 | |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | Parkinson David Ross | Director | Option Exercise | A | 3.30 | 80,000 | 264,000 | 80,000 | |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | Fischer Laurent | Director | Option Exercise | A | 3.30 | 80,000 | 264,000 | 80,000 | |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Option Exercise | A | 3.30 | 200,000 | 660,000 | 200,000 | |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Grant | A | 0.98 | 5,000 | 4,900 | 37,500 | 32.5 K to 37.5 K (+15.38 %) |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | KIRSKE DAVID | EVP, Chief Financia ... | Option Exercise | S | 3.30 | 200,000 | 660,000 | 200,000 | |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | KIRSKE DAVID | EVP, Chief Financia ... | Grant | A | 0.98 | 3,798 | 3,722 | 3,798 | 0 to 3.8 K |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | Craig Adam R | President and CEO | Option Exercise | A | 3.30 | 800,000 | 2,640,000 | 800,000 | |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | Craig Adam R | President and CEO | Grant | A | 0.98 | 5,000 | 4,900 | 5,000 | 0 to 5 K |
Mar 12 2021 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | Director | Option Exercise | A | 3.30 | 80,000 | 264,000 | 80,000 | |
Jan 11 2021 | CTIC | CTI BIOPHARMA CORP | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 3.50 | 2,000,000 | 7,000,000 | 7,520,600 | 9.5 M to 7.5 M (-21.01 %) |
Jan 11 2021 | CTIC | CTI BIOPHARMA CORP | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 3.50 | 2,000,000 | 7,000,000 | 7,520,600 | 9.5 M to 7.5 M (-21.01 %) |
Jul 02 2020 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Grant | A | 0.99 | 500 | 493 | 32,500 | 32 K to 32.5 K (+1.56 %) |
Mar 13 2020 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Option Exercise | A | 1.00 | 330,000 | 330,000 | 330,000 | |
Mar 13 2020 | CTIC | CTI BIOPHARMA CORP | KIRSKE DAVID | EVP, Chief Financia ... | Option Exercise | A | 1.00 | 350,000 | 350,000 | 350,000 | |
Mar 13 2020 | CTIC | CTI BIOPHARMA CORP | Tuckson Reed Vaughn | Director | Option Exercise | A | 1.00 | 126,000 | 126,000 | 126,000 | |
Mar 13 2020 | CTIC | CTI BIOPHARMA CORP | Parkinson David Ross | Director | Option Exercise | A | 1.00 | 126,000 | 126,000 | 126,000 | |
Mar 13 2020 | CTIC | CTI BIOPHARMA CORP | Fischer Laurent | Director | Option Exercise | A | 1.00 | 126,000 | 126,000 | 126,000 | |
Mar 13 2020 | CTIC | CTI BIOPHARMA CORP | Craig Adam R | President and CEO | Option Exercise | A | 1.00 | 2,320,000 | 2,320,000 | 2,320,000 | |
Mar 13 2020 | CTIC | CTI BIOPHARMA CORP | Metzger Michael A | Director | Option Exercise | A | 1.00 | 126,000 | 126,000 | 126,000 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | P | 10,000.00 | 12 | 120,000 | 12 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | P | 10,000.00 | 87 | 870,000 | 191 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | P | 10,000.00 | 841 | 8,410,000 | 1,250 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | P | 10,000.00 | 981 | 9,810,000 | 1,594 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 10,000.00 | 104 | 1,040,000 | 104 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 10,000.00 | 104 | 1,040,000 | 0 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 10,000.00 | 409 | 4,090,000 | 409 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 10,000.00 | 409 | 4,090,000 | 0 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 10,000.00 | 613 | 6,130,000 | 613 | |
Mar 04 2020 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | X | 10,000.00 | 613 | 6,130,000 | 0 | |
May 20 2019 | CTIC | CTI BIOPHARMA CORP | PERRY MATTHEW D | Director | Option Exercise | A | 0.84 | 120,000 | 100,932 | 120,000 | |
May 20 2019 | CTIC | CTI BIOPHARMA CORP | Fischer Laurent | Director | Option Exercise | A | 0.84 | 120,000 | 100,932 | 120,000 | |
May 20 2019 | CTIC | CTI BIOPHARMA CORP | Metzger Michael A | Director | Option Exercise | A | 0.84 | 120,000 | 100,932 | 120,000 | |
May 20 2019 | CTIC | CTI BIOPHARMA CORP | Tuckson Reed Vaughn | Director | Option Exercise | A | 0.84 | 120,000 | 100,932 | 120,000 | |
May 20 2019 | CTIC | CTI BIOPHARMA CORP | Parkinson David Ross | Director | Option Exercise | A | 0.84 | 120,000 | 100,932 | 120,000 | |
May 20 2019 | CTIC | CTI BIOPHARMA CORP | Craig Adam R | President and CEO | Option Exercise | A | 0.84 | 1,300,000 | 1,093,430 | 1,300,000 | |
Feb 21 2019 | CTIC | CTI BIOPHARMA CORP | KIRSKE DAVID | EVP, Chief Financia ... | Option Exercise | A | 0.95 | 500,000 | 474,450 | 500,000 | |
Jan 03 2019 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Grant | A | 0.62 | 500 | 312 | 32,000 | 31.5 K to 32 K (+1.59 %) |
Sep 20 2018 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Option Exercise | A | 1.88 | 125,000 | 235,000 | 125,000 | |
Sep 20 2018 | CTIC | CTI BIOPHARMA CORP | KIRSKE DAVID | EVP, Chief Financia ... | Option Exercise | A | 1.88 | 125,000 | 235,000 | 125,000 | |
Sep 20 2018 | CTIC | CTI BIOPHARMA CORP | Craig Adam R | President and CEO | Option Exercise | A | 1.88 | 600,000 | 1,128,000 | 600,000 | |
Sep 20 2018 | CTIC | CTI BIOPHARMA CORP | Telling Fred | Director | Option Exercise | A | 1.88 | 60,000 | 112,800 | 60,000 | |
Jul 02 2018 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Grant | A | 2.30 | 500 | 1,148 | 31,500 | 31 K to 31.5 K (+1.61 %) |
Jul 02 2018 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Grant | A | 2.30 | 500 | 1,148 | 31,500 | 31 K to 31.5 K (+1.61 %) |
May 21 2018 | CTIC | CTI BIOPHARMA CORP | PERRY MATTHEW D | Director | Option Exercise | A | 4.61 | 60,000 | 276,600 | 60,000 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | Fischer Laurent | Director | Option Exercise | A | 4.61 | 60,000 | 276,600 | 60,000 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | Metzger Michael A | Director | Option Exercise | A | 4.61 | 60,000 | 276,600 | 60,000 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | Parkinson David Ross | Director | Option Exercise | A | 4.61 | 60,000 | 276,600 | 60,000 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | Telling Fred | Director | Option Exercise | A | 4.61 | 60,000 | 276,600 | 60,000 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | Tuckson Reed Vaughn | Director | Option Exercise | A | 4.61 | 60,000 | 276,600 | 60,000 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | Craig Adam R | President and CEO | Option Exercise | A | 4.14 | 475,000 | 1,966,500 | 475,000 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | KIRSKE DAVID | EVP, Chief Financia ... | Option Exercise | A | 4.14 | 83,396 | 345,259 | 83,396 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Option Exercise | A | 4.14 | 134,906 | 558,511 | 134,906 | |
May 17 2018 | CTIC | CTI BIOPHARMA CORP | SINGER JACK W | EVP, Chief Scientif ... | Option Exercise | A | 4.14 | 94,433 | 390,953 | 94,433 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 2,280 | 0 | 2,280 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 2,280 | 0 | 2,280 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 1,024 | 0 | 1,024 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 1,024 | 0 | 1,024 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 3,640 | 0 | 3,640 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 3,640 | 0 | 3,640 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 5,631 | 0 | 5,631 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | A | 0.00 | 5,631 | 0 | 5,631 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 49 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 49 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 48 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 48 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 197 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 197 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 281 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | D | 0.00 | 281 | 0 | 0 | |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 699,225 | 2,097,675 | 1,295,582 | 596.4 K to 1.3 M (+117.25 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 699,225 | 2,097,675 | 1,295,582 | 596.4 K to 1.3 M (+117.25 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 483,708 | 1,451,124 | 483,708 | 0 to 483.7 K |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 483,708 | 1,451,124 | 483,708 | 0 to 483.7 K |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 2,109,280 | 6,327,840 | 2,109,280 | 0 to 2.1 M |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 2,109,280 | 6,327,840 | 2,109,280 | 0 to 2.1 M |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 3,041,120 | 9,123,360 | 3,041,120 | 0 to 3 M |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 3.00 | 3,041,120 | 9,123,360 | 3,041,120 | 0 to 3 M |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Sell | D | 0.00 | 1,487,294 | 0 | 596,357 | 2.1 M to 596.4 K (-71.38 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Sell | D | 0.00 | 1,487,294 | 0 | 596,357 | 2.1 M to 596.4 K (-71.38 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Sell | D | 0.00 | 651,074 | 0 | 0 | 651.1 K to 0 (-100.00 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Sell | D | 0.00 | 651,074 | 0 | 0 | 651.1 K to 0 (-100.00 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Sell | D | 0.00 | 2,295,083 | 0 | 0 | 2.3 M to 0 (-100.00 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Sell | D | 0.00 | 2,295,083 | 0 | 0 | 2.3 M to 0 (-100.00 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Sell | D | 0.00 | 3,566,549 | 0 | 0 | 3.6 M to 0 (-100.00 %) |
Feb 12 2018 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Sell | D | 0.00 | 3,566,549 | 0 | 0 | 3.6 M to 0 (-100.00 %) |
Jan 22 2018 | CTIC | CTI BIOPHARMA CORP | Metzger Michael A | Director | Option Exercise | M | 0.00 | 20,121 | 0 | 0 | |
Jan 22 2018 | CTIC | CTI BIOPHARMA CORP | Metzger Michael A | Director | Buy | M | 0.00 | 20,121 | 0 | 20,121 | 0 to 20.1 K |
Oct 03 2017 | CTIC | CTI BIOPHARMA CORP | Craig Adam R | President and CEO | Option Exercise | A | 3.19 | 450,000 | 1,435,500 | 450,000 | |
Oct 03 2017 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Operatin ... | Option Exercise | A | 3.19 | 350,000 | 1,116,500 | 350,000 | |
Oct 03 2017 | CTIC | CTI BIOPHARMA CORP | KIRSKE DAVID | EVP, Chief Financia ... | Option Exercise | A | 3.19 | 315,000 | 1,004,850 | 315,000 | |
Oct 03 2017 | CTIC | CTI BIOPHARMA CORP | SINGER JACK W | EVP, Chief Scientif ... | Option Exercise | A | 3.19 | 115,000 | 366,850 | 115,000 | |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.20 | 976 | 3,123 | 73,718 | 74.7 K to 73.7 K (-1.31 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.25 | 200 | 650 | 74,694 | 74.9 K to 74.7 K (-0.27 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.24 | 477 | 1,545 | 74,894 | 75.4 K to 74.9 K (-0.63 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.24 | 200 | 647 | 75,371 | 75.6 K to 75.4 K (-0.26 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.23 | 1,600 | 5,168 | 75,571 | 77.2 K to 75.6 K (-2.07 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.23 | 1,675 | 5,410 | 77,171 | 78.8 K to 77.2 K (-2.12 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.23 | 25 | 81 | 78,846 | 78.9 K to 78.8 K (-0.03 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.22 | 600 | 1,932 | 78,871 | 79.5 K to 78.9 K (-0.75 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.22 | 100 | 322 | 79,471 | 79.6 K to 79.5 K (-0.13 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.21 | 1,000 | 3,210 | 79,571 | 80.6 K to 79.6 K (-1.24 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.21 | 100 | 321 | 80,571 | 80.7 K to 80.6 K (-0.12 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.21 | 200 | 641 | 80,671 | 80.9 K to 80.7 K (-0.25 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.20 | 2,747 | 8,790 | 80,871 | 83.6 K to 80.9 K (-3.29 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.20 | 700 | 2,237 | 83,618 | 84.3 K to 83.6 K (-0.83 %) |
Oct 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Sell | S | 3.19 | 4,000 | 12,760 | 84,318 | 88.3 K to 84.3 K (-4.53 %) |
Sep 22 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Option Exercise | A | 4.25 | 50,000 | 212,500 | 50,000 | |
Aug 03 2017 | CTIC | CTI BIOPHARMA CORP | KIRSKE DAVID | See Remarks | Option Exercise | A | 3.43 | 25,000 | 85,750 | 25,000 | |
Jul 25 2017 | CTIC | CTI BIOPHARMA CORP | Fischer Laurent | Director | Option Exercise | A | 3.41 | 50,000 | 170,500 | 50,000 | |
Jun 15 2017 | CTIC | CTI BIOPHARMA CORP | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 7,500 | 0 | 0 | |
Jun 15 2017 | CTIC | CTI BIOPHARMA CORP | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 5,000,000 | 0 | 5,000,000 | 0 to 5 M |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | C | 0.00 | 536 | 0 | 49 | |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | C | 0.00 | 513 | 0 | 48 | |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | C | 0.00 | 2,115 | 0 | 197 | |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | C | 0.00 | 3,011 | 0 | 281 | |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | P | 0.00 | 585 | 0 | 585 | |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | P | 0.00 | 561 | 0 | 561 | |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | P | 0.00 | 2,312 | 0 | 2,312 | |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Option Exercise | P | 0.00 | 3,292 | 0 | 3,292 | |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | C | 0.00 | 357,333 | 0 | 2,083,651 | 1.7 M to 2.1 M (+20.70 %) |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | C | 0.00 | 342,000 | 0 | 651,074 | 309.1 K to 651.1 K (+110.65 %) |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | C | 0.00 | 1,410,000 | 0 | 2,295,083 | 885.1 K to 2.3 M (+159.31 %) |
Jun 14 2017 | CTIC | CTI BIOPHARMA CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | C | 0.00 | 2,007,333 | 0 | 3,566,549 | 1.6 M to 3.6 M (+128.74 %) |
Jun 07 2017 | CTIC | CTI BIOPHARMA CORP | Parkinson David Ross | Director | Option Exercise | A | 4.07 | 50,000 | 203,500 | 50,000 | |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | PERRY MATTHEW D | Director | Option Exercise | M | 0.00 | 34,736 | 0 | 0 | |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | PERRY MATTHEW D | Director | Buy | M | 0.00 | 34,736 | 0 | 43,139 | 8.4 K to 43.1 K (+413.38 %) |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Option Exercise | M | 0.00 | 34,736 | 0 | 0 | |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | LOVE RICHARD L | Director | Buy | M | 0.00 | 34,736 | 0 | 88,318 | 53.6 K to 88.3 K (+64.83 %) |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | Telling Fred | Director | Option Exercise | M | 0.00 | 34,736 | 0 | 0 | |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | Telling Fred | Director | Buy | M | 0.00 | 34,736 | 0 | 78,874 | 44.1 K to 78.9 K (+78.70 %) |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Option Exercise | M | 0.00 | 39,698 | 0 | 0 | |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | NUDELMAN PHILLIP M PHD | Director | Buy | M | 0.00 | 39,698 | 0 | 73,129 | 33.4 K to 73.1 K (+118.75 %) |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | Tuckson Reed Vaughn | Director | Option Exercise | M | 0.00 | 34,736 | 0 | 0 | |
May 02 2017 | CTIC | CTI BIOPHARMA CORP | Tuckson Reed Vaughn | Director | Buy | M | 0.00 | 34,736 | 0 | 92,424 | 57.7 K to 92.4 K (+60.21 %) |
Mar 21 2017 | CTIC | CTI BIOPHARMA CORP | Craig Adam R | See Remarks | Option Exercise | A | 4.24 | 1,200,000 | 5,088,000 | 1,200,000 | |
Mar 06 2017 | CTIC | CTI BIOPHARMA CORP | SEELEY BRUCE J. | EVP, Chief Commerci ... | Option Exercise | A | 4.33 | 60,000 | 259,800 | 60,000 | |
Mar 06 2017 | CTIC | CTI BIOPHARMA CORP | Plunkett Matthew | EVP, Chief Business ... | Option Exercise | A | 4.33 | 60,000 | 259,800 | 60,000 | |
Mar 06 2017 | CTIC | CTI BIOPHARMA CORP | SINGER JACK W | EVP, Chief Scientif ... | Option Exercise | A | 4.33 | 60,000 | 259,800 | 60,000 | |
Feb 27 2017 | CTIC | CTI BIOPHARMA CORP | PERRY MATTHEW D | Director | Option Exercise | A | 4.25 | 50,000 | 212,500 | 50,000 | |
Feb 27 2017 | CTIC | CTI BIOPHARMA CORP | Tuckson Reed Vaughn | Director | Option Exercise | A | 4.25 | 50,000 | 212,500 | 50,000 | |
Feb 27 2017 | CTIC | CTI BIOPHARMA CORP | Telling Fred | Director | Option Exercise | A | 4.25 | 50,000 | 212,500 | 50,000 |